Free Trial

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $16.56 Consensus Target Price from Brokerages

BioCryst Pharmaceuticals logo with Medical background

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $16.56.

A number of equities research analysts have issued reports on BCRX shares. Needham & Company LLC boosted their price target on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. JPMorgan Chase & Co. boosted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research report on Tuesday, May 6th. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 22nd. Finally, Wedbush began coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price objective for the company.

Read Our Latest Report on BCRX

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Headlands Technologies LLC bought a new position in shares of BioCryst Pharmaceuticals in the first quarter worth about $32,000. GF Fund Management CO. LTD. bought a new position in BioCryst Pharmaceuticals in the 4th quarter worth approximately $33,000. GAMMA Investing LLC grew its holdings in BioCryst Pharmaceuticals by 1,161.8% during the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after buying an additional 5,449 shares in the last quarter. Venturi Wealth Management LLC purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth $46,000. Finally, R Squared Ltd bought a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth $48,000. Institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX traded down $0.15 during midday trading on Wednesday, hitting $10.73. 3,215,552 shares of the stock traded hands, compared to its average volume of 3,027,240. The firm has a market capitalization of $2.25 billion, a P/E ratio of -17.59 and a beta of 1.08. BioCryst Pharmaceuticals has a one year low of $5.92 and a one year high of $11.11. The firm has a 50-day moving average of $8.66 and a two-hundred day moving average of $8.15.

About BioCryst Pharmaceuticals

(Get Free Report

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

See Also

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Should You Invest $1,000 in BioCryst Pharmaceuticals Right Now?

Before you consider BioCryst Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.

While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This Unique Robotaxi Play Could Deliver 10X Returns
NVIDIA’s Secret Picks? 3 Stocks Rising With the AI Giant
NVIDIA Earnings Preview: HUGE Stock Move Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines